Characteristics and Production of Monoclonal Antibodies

Clinical Examples

To understand these in practice, consider these common therapeutics:

• Rituximab (-ximab): Used for lymphoma and autoimmune diseases by targeting the CD20 antigen on B cells.
• Trastuzumab (-zumab): Used in breast cancer treatment by targeting the HER2 receptor.
• Ofatumumab (-umab): Used in the treatment of multiple sclerosis to deplete B cells.

Exam Tip: If you see a drug name ending in -umab, it is the most "human" version and is least likely to cause an adverse immune response in a patient compared to an -omab drug.

Applications in Oncology

Monoclonal antibodies have revolutionized cancer treatment by allowing for targeted therapy that spares healthy cells. In oncology, mAbs are categorized by how they interact with the tumor:

1. Naked mAbs: These act as a standalone therapy, using the antibody itself to trigger an immune response or block a receptor.
2. Conjugated mAbs: These are "tagged" or "loaded" with other agents. They might be attached to radioactive particles or combined with traditional chemotherapy to deliver the toxic payload directly to the cancer cell.
3. Bispecific mAbs: These are engineered to be dual-purpose, capable of targeting and attacking two different specific antigens simultaneously.

The Production Process: Hybridoma Technology

The production of mAbs relies on hybridoma technology, a method that combines the antibody-producing ability of B cells with the infinite lifespan of cancer cells.

Step-by-Step Workflow

The generation of a hybridoma follows a systematic multi-step process:

1. Immunization and Isolation: A mouse is immunized with a specific antigen. Once the immune response is active, antibody-producing splenocytes (spleen cells) are isolated from the mouse.
2. Myeloma Preparation: Immortalized myeloma cells are prepared. These cells are essential because, while splenocytes produce antibodies, they cannot divide indefinitely in culture.
3. Cell Fusion: The splenocytes and myeloma cells are mixed together. Polyethylene glycol (PEG) is added to the mixture to facilitate the fusion of the cell membranes, resulting in a single "hybrid" cell called a hybridoma.
4. Clone Screening and Selection: Not all fused cells will be useful. Scientists screen the resulting clones to find those that possess both the immortality of the myeloma and the specific antigen affinity of the splenocyte.
5. Functional Characterization: High-producing colonies are validated using assays such as ELISA (Enzyme-Linked Immunosorbent Assay) to ensure they produce the correct immunoglobulin class and target the intended epitope.
6. Scale-up and Expansion: Once a perfect clone is identified, it is "weaned" off selection agents and expanded in large-scale systems, such as hollow fibre bioreactors or large spinner flasks, to produce industrial quantities of the antibody.

As the global market for these therapies continues to grow—projected to surpass 547.3 billion USD by 2033—the refinement of these production techniques remains vital for treating autoimmune, infectious, and neurological disorders.